The DEEP project has received research funding from the European Union under the 7th Framework Programme

recruiting centres

VII DEEP General Assembly Meeting in Padua 2016

agosto 14, 2016
|
Comments off
|

After the sad decision to cancel the General Assembly (GA) meeting in Tunis, due to the disorders which have occurred across the Country, the 7th DEEP General Assembly was held in Padua, Italy between April 13th and 15th, 2016 with the participation of the whole DEEP […]

Share
Read more →

DEEP-2: an update of the clinical centres involved

ottobre 30, 2015
|
Comments off
|

Another step forward has been made toward the enrollment of new patients in the DEEP-2 study, a phase III multicentre, randomised, open label, non-inferiority active-controlled trial aiming at comparing for the first time the efficacy of deferiprone (DFP) vs deferasirox (DFX) in paediatric patients affected […]

Share
Read more →

DEEP-3: an update on the observational study

ottobre 30, 2015
|
Comments off
|

DEEP-3 is a long-term observational safety study which evaluates the nature and incidence of adverse effects of deferiprone (DFP) in children and adolescents with beta-thalassaemia major and currently involves 18 recruiting centres from 7 different countries: Albania, Cyprus, Greece, Egypt, Italia, Morocco and Tunisia.

On […]

Share
Read more →

Update of Centres involved

agosto 3, 2015
|
Comments off
|

Another step forward has been made toward the enrollment of new patients, which is allowed by the end of October 2015.

Principal Investigators (PIs) are still working to continue the enrollment of patients within the DEEP-2 study and to date a total of 117 patients have been […]

Share
Read more →